Illinois pharmacy compounding regulations sit in two layers: state rules administered by the Illinois Department of Financial and Professional Regulation (IDFPR) through its Board of Pharmacy, and federal rules under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.1Illinois Department of Financial and Professional Regulation. State Board of Pharmacy The state incorporates United States Pharmacopeia (USP) compounding standards directly into its administrative code, so a pharmacy that compounds in Illinois has to satisfy USP, the Pharmacy Practice Act, and whichever federal track applies to it. Violations can carry fines up to $10,000 each, suspension of compounding privileges, or loss of the pharmacy license.
What Illinois Lets You Compound
Illinois defines compounding as preparing and mixing drug components based on a prescriber’s order within the prescriber-patient-pharmacist relationship. Pharmacies may also compound in anticipation of prescriptions when the formulas match routine, regularly observed dispensing patterns. Speculative production for general inventory is not allowed.
The sharpest limit involves commercially available products. An Illinois pharmacy can only compound a drug that already exists on the market when the commercial version is not reasonably available through normal distribution channels in a timely manner and the prescriber has specifically requested the compounded version.
Federal law layers an additional restriction on top. Under Section 503A, a pharmacy cannot routinely compound drugs that are “essentially copies” of commercially available products. The FDA treats a compounded drug as essentially a copy when it has the same active ingredient, the same or easily substitutable strength, and the same route of administration as a marketed product.2U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A A prescriber can override that restriction by documenting a “significant difference” for a specific patient on the prescription, such as an allergy to a dye in the commercial version or an inability to swallow tablets. Lower price alone does not qualify.
As an enforcement threshold, the FDA has said it will not pursue a pharmacy for compounding an essential copy if the pharmacy fills four or fewer prescriptions for that formulation in a calendar month, counting each refill as a separate prescription. A drug is not considered commercially available if it has been discontinued or appears on the FDA’s drug shortage list.
Who Can Compound and Under What License
Any pharmacy that compounds in Illinois must hold a valid pharmacy license under the Pharmacy Practice Act (225 ILCS 85). All compounding activities have to stay under the direct supervision of the pharmacist-in-charge. Operating without proper registration can trigger a cease-and-desist order or revocation of the business license.
Pharmacy technicians may assist with compounding, but the pharmacy and its pharmacist-in-charge share responsibility for training them in compounding, packaging, labeling, and storage. That training must be completed within six months of the technician’s initial employment or any change in their duties.3Illinois General Assembly. Illinois Administrative Code Title 68 Section 1330.210 – Pharmacy Technician Training Training is not a one-time event. Pharmacists have to maintain ongoing competency through continuing education in sterile or non-sterile techniques, and the documentation needs to be available for inspection.
A pharmacy that intends to provide sterile compounding services must specifically notify the Board of Pharmacy. That notification triggers more rigorous inspection protocols than those applied to standard community pharmacies. Starting sterile compounding without notifying the Board puts the pharmacy outside the scope of its license and every prescription filled during that period at legal risk.
Facility and Equipment Standards
Illinois Administrative Code Section 1330.640 requires all pharmaceutical compounding to follow the standards in the official USP-NF, currently the 2024 edition (USP 47-NF 42).4Legal Information Institute. Illinois Administrative Code Title 68 Section 1330.640 – Pharmaceutical Compounding Standards In practice, non-sterile compounding must meet USP Chapter 795 and sterile compounding must meet USP Chapter 797. Illinois does not incorporate USP Chapter 800 (handling of hazardous drugs) into its compounding regulations, but federal OSHA requirements, institutional policies, and accrediting bodies may still require compliance.
Non-Sterile Compounding Areas
Pharmacies performing non-sterile compounding must maintain dedicated areas separated from general prescription filling to prevent cross-contamination. Floors, walls, and ceilings have to be non-porous and able to withstand frequent chemical disinfection. Lighting and ventilation must control heat and moisture that could compromise ingredient stability. Equipment used for non-sterile compounding has to be verified for accuracy at least every 12 months according to manufacturer specifications.5Illinois Department of Financial and Professional Regulation. Non-Sterile Compounding Pharmacy Self-Inspection Form
Sterile Compounding Areas
Sterile compounding carries a much higher environmental burden. The core requirement is a Primary Engineering Control (PEC), such as a laminar airflow workbench, biological safety cabinet, or compounding aseptic isolator, that provides an ISO Class 5 environment. These devices must be professionally certified and tested at least every six months, and whenever they are relocated, altered, or undergo major service. Pharmacies also need pressure-monitored buffer areas and ante-rooms to isolate the compounding process from the surrounding environment. Failure to maintain required air quality can lead to immediate suspension of compounding privileges during a state audit.
Environmental Monitoring
USP 797 requires ongoing environmental monitoring. Viable air sampling must be performed at least every six months for Category 1 and Category 2 compounded sterile preparations, and at least monthly for Category 3. Surface sampling must occur at least monthly for Categories 1 and 2, and at least weekly for Category 3. Failing to document these checks is one of the most common inspection findings.
Hazardous Drug Compounding
Even though Illinois excludes USP 800 from its compounding code, pharmacies that handle hazardous drugs still face real constraints in practice. USP 800 calls for a containment primary engineering control inside an externally vented, negative-pressure room with at least 12 air changes per hour. Sterile hazardous compounding requires a C-PEC providing ISO Class 5 air; laminar airflow workbenches cannot be used for antineoplastic drugs. Pharmacies should check whether their accrediting bodies, institutional policies, or federal workplace safety rules independently require USP 800 compliance regardless of the state exemption.
Labeling Every Compounded Prescription
Every compounded drug dispensed to a patient in Illinois must carry a permanent label with a specific set of information under Section 1330.640:6Illinois General Assembly. Illinois Administrative Code Title 68 Part 1330
- Name, address, and telephone number of the licensed pharmacy, if the drug is used outside the facility
- Date dispensed and an identifying number for off-site use
- Patient’s name and room number, if applicable
- Name of each drug component, strength, amount, and dosage form
- Directions for use or infusion rate for off-site use
- Prescriber’s name for off-site use
- Beyond-use date (and time, if appropriate)
- Controlled substance transfer warnings when applicable
- Auxiliary label with storage conditions such as refrigeration or light protection, if applicable
The Beyond Use Date (BUD) is not the same as a manufacturer’s expiration date. It reflects the stability characteristics of the custom formulation and varies by category under the revised USP 797.
Drugs compounded for “office use” by practitioners carry additional labeling: the statement “For Office Use Only – Not for Resale,” along with the pharmacy’s lot number and beyond-use date.4Legal Information Institute. Illinois Administrative Code Title 68 Section 1330.640 – Pharmaceutical Compounding Standards Preparations containing hazardous substances need auxiliary warning labels. A non-compliant label can cause a medication to be deemed misbranded, which creates direct legal liability for the dispensing pharmacist.
Record Keeping
Illinois compounding rules, drawn from USP 795, require two foundational documents for every formulation.
Master Formulation Record
The Master Formulation Record is the permanent recipe for a specific preparation. It must include the preparation’s name, strength, and dosage form; all ingredients and their quantities; compatibility and stability information with references; the equipment needed; step-by-step mixing instructions covering order, temperature, duration, and other critical variables; packaging and storage requirements; a description of the expected final product; and quality control procedures with expected results.
Compounding Record
Each time a pharmacy actually prepares a batch, it creates a Compounding Record tied to the relevant Master Formulation Record. The batch log must capture the sources, lot numbers, and expiration dates of all ingredients used; the total quantity compounded; the names of the person who prepared it, the person who performed quality control, and the pharmacist who approved it; the preparation date; the assigned control or prescription number; the assigned BUD; a duplicate of the label; a description of the final preparation; and the quality control results.4Legal Information Institute. Illinois Administrative Code Title 68 Section 1330.640 – Pharmaceutical Compounding Standards
Retention
Illinois requires pharmacies to retain all compounding records for at least five years.7Legal Information Institute. Illinois Administrative Code Title 77 Section 3100.360 – Record and Inventorying Requirements Generally During an IDFPR inspection, records must be readily accessible. Office-use records must additionally document the practitioner’s name and address, the order date, the compounded drug’s name, strength, quantity, lot number, BUD, and the date provided to the practitioner.6Illinois General Assembly. Illinois Administrative Code Title 68 Part 1330 A single missing lot number is a correctable error. A pattern of incomplete batch records can trigger probation or a formal corrective action plan.
The Federal Track: 503A or 503B
On top of state rules, every Illinois compounding pharmacy falls into one of two federal categories, and which one applies shapes what the pharmacy is allowed to produce.
Most community pharmacies in Illinois compound under Section 503A. Compounded drugs prepared under 503A are exempt from FDA new-drug approval, current good manufacturing practice (CGMP) requirements, and the standard labeling mandate for adequate directions for use, as long as the conditions are met.8U.S. Food and Drug Administration. FDC Act Provisions that Apply to Human Drug Compounding The central condition is that compounding has to be based on a valid prescription for an identified individual patient. Limited anticipatory compounding is allowed based on regular dispensing patterns.
Section 503B covers outsourcing facilities. These facilities register with the FDA, comply with CGMP, report adverse events, and submit a list of compounded drugs to the FDA every six months.9U.S. Food and Drug Administration. Information for Outsourcing Facilities In exchange, 503B facilities can compound without patient-specific prescriptions, which lets them produce drugs for “office use” by healthcare providers or for hospital stock. Their labels must include the statement “This is a compounded drug.” Operating as a 503B facility does not exempt a pharmacy from Illinois licensing and inspection requirements.
Penalties for Getting It Wrong
The IDFPR has broad disciplinary authority under Section 30 of the Pharmacy Practice Act. For any violation, the Department can refuse to issue or renew a license, revoke or suspend a license, place a licensee on probation, or impose fines up to $10,000 per violation.10Illinois General Assembly. Illinois Compiled Statutes 225 ILCS 85/30 Fines can be combined with other disciplinary actions but cannot be the sole penalty when the violation resulted in patient death or injury.
For less severe infractions, the Department can issue citations under Section 35.21 of the Act. Citations carry a maximum penalty of $3,000 and are typically used for violations that fall short of full disciplinary proceedings. Each citation must include a factual statement, the specific sections violated, and the penalty imposed.
The consequences reach beyond the fine itself. A disciplinary action becomes part of the pharmacist’s or pharmacy’s public record and can affect insurance credentialing, hospital privileges, and professional reputation long after the money is paid. Pharmacies that receive inspection findings usually have a window to submit a corrective action plan before the Board escalates to formal discipline. That window closes quickly once a pattern of non-compliance is established.